FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030622134> ?p ?o ?g. }

• W3030622134 abstract "11546 Background: Despite several second-line options are accessible for the treatment of advanced STS, there is a lack of predictive biomarkers available to support the rational selection of these drugs. Trabectedin specifically targets mononuclear cell lineage (macrophages and monocytes) that ultimately could inhibit tumor angiogenesis. Moreover, trabectedin seems to induce the expression of immune-checkpoint proteins (e.g. PD-L1); however, the predictive value of these factors remains unknown. We present the analyses of immune-checkpoint genes ( CD274, CD86, CTLA4, HAVCR2, LAG3 and PDCD1) and CD163, CD4, CD68 and CD8A expression as potential predictive factors of response to trabectedin in a subset of STS patients of the GEIS registry. Methods: Selection criteria included patients with STS, pretreated with at least 2 lines in the advanced setting (one line being trabectedin), with paraffin block available and ethic committee’s approval. Direct transcriptomics was performed using HTG Molecular Oncology Biomarker Pathway panel (HTG Molecular Diagnostics, Inc.; Tucson, AZ, USA), following manufacturers’ instructions. Data analyses were performed taking into account the median Log2 of expression of each gene and by correlating it with progression-free survival (PFS) for trabectedin, and overall survival measured from the starting date of trabectedin treatment (OS). Results: Among 387 registered patients, fitting with the inclusions criteria, 139 cases were used for gene expression analyses, as the discovery set. Patients had median age of 52 years, 54% were females and had a median follow-up from diagnosis of 44 months. High expression of CD274 (PD-L1) was significantly associated with better PFS of trabectedin (5.4 vs. 3.0 months; p= 0.006). Similar results were obtained with high expression of CTLA4 and LAG3: 6.0 vs 3.1 months; p = 0.005 and 5.4 vs 2.7 months; p = 0.042, respectively. Expression of CTLA4 and LAG3 showed no significant impact in OS; whereas CD274 high expression showed a trend towards better OS (17.9 vs 10.2 months; p = 0.077). Also, no significant correlation was achieved for CD163, CD4, CD68, CD8A, CD86 and HAVCR2; PDCD1 (PD-1) showed a trend towards better PFS of trabectedin, p = 0.114. Conclusions: The expression of selected immune-checkpoint genes exhibited a potential predictive value for trabectedin in advanced STS. Validation studies (at the transcriptional and protein level) are currently ongoing to confirm their potential predictive role." @default.
• W3030622134 created "2020-06-05" @default.
• W3030622134 creator A5006074198 @default.
• W3030622134 creator A5013226419 @default.
• W3030622134 creator A5015310203 @default.
• W3030622134 creator A5018070882 @default.
• W3030622134 creator A5020381519 @default.
• W3030622134 creator A5030814587 @default.
• W3030622134 creator A5035080036 @default.
• W3030622134 creator A5040105917 @default.
• W3030622134 creator A5040364707 @default.
• W3030622134 creator A5048535717 @default.
• W3030622134 creator A5056218323 @default.
• W3030622134 creator A5057133602 @default.
• W3030622134 creator A5060106294 @default.
• W3030622134 creator A5063392090 @default.
• W3030622134 creator A5075323885 @default.
• W3030622134 creator A5079509286 @default.
• W3030622134 creator A5081453760 @default.
• W3030622134 creator A5082287639 @default.
• W3030622134 creator A5084299266 @default.
• W3030622134 creator A5090906445 @default.
• W3030622134 date "2020-05-20" @default.
• W3030622134 modified "2023-10-01" @default.
• W3030622134 title "Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study." @default.
• W3030622134 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.11546" @default.
• W3030622134 hasPublicationYear "2020" @default.
• W3030622134 type Work @default.
• W3030622134 sameAs 3030622134 @default.
• W3030622134 citedByCount "0" @default.
• W3030622134 crossrefType "journal-article" @default.
• W3030622134 hasAuthorship W3030622134A5006074198 @default.
• W3030622134 hasAuthorship W3030622134A5013226419 @default.
• W3030622134 hasAuthorship W3030622134A5015310203 @default.
• W3030622134 hasAuthorship W3030622134A5018070882 @default.
• W3030622134 hasAuthorship W3030622134A5020381519 @default.
• W3030622134 hasAuthorship W3030622134A5030814587 @default.
• W3030622134 hasAuthorship W3030622134A5035080036 @default.
• W3030622134 hasAuthorship W3030622134A5040105917 @default.
• W3030622134 hasAuthorship W3030622134A5040364707 @default.
• W3030622134 hasAuthorship W3030622134A5048535717 @default.
• W3030622134 hasAuthorship W3030622134A5056218323 @default.
• W3030622134 hasAuthorship W3030622134A5057133602 @default.
• W3030622134 hasAuthorship W3030622134A5060106294 @default.
• W3030622134 hasAuthorship W3030622134A5063392090 @default.
• W3030622134 hasAuthorship W3030622134A5075323885 @default.
• W3030622134 hasAuthorship W3030622134A5079509286 @default.
• W3030622134 hasAuthorship W3030622134A5081453760 @default.
• W3030622134 hasAuthorship W3030622134A5082287639 @default.
• W3030622134 hasAuthorship W3030622134A5084299266 @default.
• W3030622134 hasAuthorship W3030622134A5090906445 @default.
• W3030622134 hasConcept C126322002 @default.
• W3030622134 hasConcept C142724271 @default.
• W3030622134 hasConcept C143998085 @default.
• W3030622134 hasConcept C2778256501 @default.
• W3030622134 hasConcept C2778629024 @default.
• W3030622134 hasConcept C2780752271 @default.
• W3030622134 hasConcept C2781197716 @default.
• W3030622134 hasConcept C502942594 @default.
• W3030622134 hasConcept C54355233 @default.
• W3030622134 hasConcept C71924100 @default.
• W3030622134 hasConcept C86803240 @default.
• W3030622134 hasConceptScore W3030622134C126322002 @default.
• W3030622134 hasConceptScore W3030622134C142724271 @default.
• W3030622134 hasConceptScore W3030622134C143998085 @default.
• W3030622134 hasConceptScore W3030622134C2778256501 @default.
• W3030622134 hasConceptScore W3030622134C2778629024 @default.
• W3030622134 hasConceptScore W3030622134C2780752271 @default.
• W3030622134 hasConceptScore W3030622134C2781197716 @default.
• W3030622134 hasConceptScore W3030622134C502942594 @default.
• W3030622134 hasConceptScore W3030622134C54355233 @default.
• W3030622134 hasConceptScore W3030622134C71924100 @default.
• W3030622134 hasConceptScore W3030622134C86803240 @default.
• W3030622134 hasLocation W30306221341 @default.
• W3030622134 hasOpenAccess W3030622134 @default.
• W3030622134 hasPrimaryLocation W30306221341 @default.
• W3030622134 hasRelatedWork W10451207 @default.
• W3030622134 hasRelatedWork W14536495 @default.
• W3030622134 hasRelatedWork W15381736 @default.
• W3030622134 hasRelatedWork W16679105 @default.
• W3030622134 hasRelatedWork W16782808 @default.
• W3030622134 hasRelatedWork W16799655 @default.
• W3030622134 hasRelatedWork W17087645 @default.
• W3030622134 hasRelatedWork W4105886 @default.
• W3030622134 hasRelatedWork W18244369 @default.
• W3030622134 hasRelatedWork W4007547 @default.
• W3030622134 isParatext "false" @default.
• W3030622134 isRetracted "false" @default.
• W3030622134 magId "3030622134" @default.
• W3030622134 workType "article" @default.